EOLS - Evolus down 13% on 2022 guidance below estimates wider-than-expected Q2 loss

• Evolus ( NASDAQ: EOLS ) is trading down ~13% after the company posted mixed results for the second quarter and full-year guidance that missed estimates.
• The company reaffirmed 2022 net revenue guidance of upper end of $143M to $150M vs. consensus of $150.27M.
• Q2 GAAP EPS was -$0.42 and missed estimates by $0.11.
• Revenue rose 42.5% Y/Y to $37.2M, but beat estimates by $0.55M, driven primarily by higher volumes and a slightly higher average selling price of Jeuveau.
• Evolus added 590 new customer accounts during the quarter.
• Operating expenses increased 18% Y/Y to $58.5M in the quarter.
• Cash at June 30 was $84.5M.
• The company said it remains on track to launch Nuceiva in Europe beginning in the third quarter of 2022.

For further details see: